ALACHUA, Fla. (Business Wire EON/PRWEB ) December 10, 2007 -- Banyan Biomarkers, Inc. announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,291,710 “Detection of spectrin and spectrin proteolytic cleavage products in assessing nerve cell damage”, licensed exclusively by Banyan Biomarkers from the University of Florida. The detection of spectrin and spectrin breakdown products in patients’ blood will allow physicians to determine the magnitude of injury and the progression of neuronal cell death after injury, thus aiding in the diagnosis of brain injuries.

Banyan and the University of Florida have filed additional patent applications claiming the use of other protein biomarkers as aids in the detection and evaluation of traumatic brain injury.

“Securing this patent is a significant achievement for Banyan Biomarkers and confirms the value and importance of our biomarker discovery and product development strategy. Banyan will continue to strengthen its intellectual property base as we carve out our place in the in vitro diagnostics medical field,” commented Gary Ascani, Chief Executive Officer of Banyan Biomarkers, Inc.

Approximately 1.9 million brain injuries are sustained annually. In a comparison provided by the Brain Injury Association of America, more traumatic brain injuries occur annually than the combined incidences of multiple sclerosis, spinal cord injuries, HIV/AIDS and breast cancer.

Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury. The company is focused on developing a simple point-of-care blood test that will be used by physicians to detect the presence and severity of brain trauma and improve the medical management of head injured patients. To learn more about Banyan Biomarkers, Inc., visit www.banyanbio.com

Home